Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus FOAMICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus FOAMICON.
ALA-SCALP vs FOAMICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
FOAMICON is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Topical application of a 5% solution to the scalp twice daily.
Adults: 200 mg orally once daily, with or without food.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life 12-15 hours; clinically, steady-state achieved in ~3 days.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily renal (65% unchanged, 15% as inactive metabolites); biliary/fecal 20%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid